Hi-Line Capital Management’s AbbVie ABBV Stock Holding History

Hi-Line Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-35,982	Closed	-$6.55M	–	34
2024 Q1	$6.55M	Buy	35,982 +505	+1%	+$87K	2.33%	15
2023 Q4	$5.5M	Sell	35,477 -3,419	-9%	-$498K	2.13%	19
2023 Q3	$5.8M	Sell	38,896 -108	-0.3%	-$15.9K	2.14%	19
2023 Q2	$5.25M	Sell	39,004 -4,685	-11%	-$687K	1.95%	18
2023 Q1	$6.96M	Sell	43,689 -28,441	-39%	-$4.35M	2.38%	18
2022 Q4	$11.7M	Buy	72,130 +216	+0.3%	+$33.1K	3.6%	12
2022 Q3	$9.65M	Buy	71,914 +1,654	+2%	+$237K	3.89%	12
2022 Q2	$10.8M	Buy	70,260 +1,760	+3%	+$269K	4.09%	11
2022 Q1	$11.1M	Buy	68,500 +654	+1%	+$95K	3.79%	11
2021 Q4	$9.19M	Buy	67,846 +80	+0.1%	+$9.45K	3.38%	13
2021 Q3	$7.31M	Buy	67,766 +2,120	+3%	+$242K	2.61%	16
2021 Q2	$7.39M	Buy	65,646 +259	+0.4%	+$29.2K	2.81%	15
2021 Q1	$7.08M	Buy	+65,387	New	+$6.99M	2.83%	15

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Hi-Line Capital Management's ABBV Position: Q2 2024 in Review

Hi-Line Capital Management sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 35,982 shares — an estimated $6.55M sold.

Hi-Line Capital Management first reported a position in ABBV in Q1 2021 and held it in 13 quarters. The position peaked at $11.7M in Q4 2022. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Hi-Line Capital Management reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Hi-Line Capital Management sold 35,982 AbbVie shares in Q2 2024, an estimated $6.55M.
Hi-Line Capital Management first reported a position in AbbVie in Q1 2021 and held it in 13 quarters.
Hi-Line Capital Management's AbbVie position peaked at $11.7M in Q4 2022.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Hi-Line Capital Management's 13F filing for Q2 2024, filed 31 Jul 2024.